Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCA-FA: Anticoagulant Therapy Managed by Implantable Device and Telecardiology in ACS With de novo Atrial Fibrillation
2024-515433-15-02Phase 4Authorised
- Sponsor
- Centre Hospitalier de Pau
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of rivaroxaban and warfarin in acute coronary syndrome (ACS) and Atrial fibrillation (AFib) (2 arms), sponsored by Centre Hospitalier de Pau. Primary endpoint: Bleeding events by BARC scale. Planned start Jan 2025; status: authorised.
02
Drugs
rivaroxabanwarfarin
03
Conditions
acute coronary syndrome (ACS)Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2024-515433-15-02.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515433-15-02.